Coley Pharma Profile
Key Indicators
- Authorised Capital ₹ 10.00 Cr
as on 09-12-2024
- Paid Up Capital ₹ 9.50 Cr
as on 09-12-2024
- Company Age 2 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
About Coley Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 10.00 Cr and a paid-up capital of Rs 9.50 Cr, as per Ministry of Corporate Affairs (MCA) records.
Pameela Paruchuri, Nagesh Middey, Venkata Jagarlamudi, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24299TG2022PTC167815
- Company No.
167815
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Oct 2022
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Coley Pharma?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pameela Paruchuri  | Director | 15-Feb-2024 | Current |
| Nagesh Middey | Director | 09-Oct-2023 | Current |
| Venkata Jagarlamudi | Director | 09-Oct-2023 | Current |
| Sri Pendyala | Director | 28-Oct-2022 | Current |
| Arvind Gannimitta | Director | 28-Oct-2022 | Current |
Financial Performance of Coley Pharma.
Enhance accessibility to Coley Pharma's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Coley Pharma?
Unlock access to Coley Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Questus Pharma Private LimitedActive 3 years 4 monthsPameela Paruchuri, Nagesh Middey and 1 more are mutual person
Halsted Pharma Private LimitedActive 2 years 3 monthsNagesh Middey and Venkata Jagarlamudi are mutual person
- Prathyak Laboratories Private LimitedActive 2 years 3 months
Nagesh Middey, Venkata Jagarlamudi and 2 more are mutual person
- Vivint Pharma Private LimitedActive 2 years 4 months
Nagesh Middey and Venkata Jagarlamudi are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Coley Pharma?
Coley Pharma has a workforce of 0 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Coley Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Coley Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
